Data di Pubblicazione:
2021
Abstract:
Neuroendocrine neoplasms (NENs) are a heterogeneous group of tumors, their treatment being challenging and requiring a multidisciplinary approach. Though the only curative treatment is surgery, up to 50% of patients are diagnosed with metastatic disease. In the last years, neoadjuvant chemo(radio)therapy has become part of the standard of care in the treatment of different cancer types. However, evidence of its efficacy and safety in NEN patients has not yet been confirmed in the literature. The aim of the present review is to perform an extensive review of the scientific evidence for neoadjuvant therapy in patients with gastroenteropancreatic and thoracic NENs.
Tipologia CRIS:
14.a.1 Articolo su rivista
Keywords:
capecitabine; chemotherapy; everolimus; neuroendocrine tumors; peptide receptor radionuclide therapy; somatostatin (analogs and derivatives); temozolomide
Elenco autori:
Lania, A.; Ferrau, F.; Rubino, M.; Modica, R.; Colao, A.; Faggiano, A.
Link alla scheda completa:
Pubblicato in: